Making regulation responsive to commercial interests: streamlining drug industry watchdogs

被引：14
|
作者：
Abraham, J [1 ]
机构：
[1] Univ Sussex, Sch Social Sci, Brighton BN1 9SN, E Sussex, England
来源：
BRITISH MEDICAL JOURNAL | 2002年 / 325卷 / 7373期
关键词：
D O I：
10.1136/bmj.325.7373.1164
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1164 / 1167
页数：4
相关论文
共 50 条
  • [31] Recombinant Drug Development, Regulation, and Commercialization An Indian Industry Perspective
    Sahoo, Niharika
    Manchikanti, Padmavati
    BIODRUGS, 2011, 25 (02) : 105 - 113
  • [32] Recombinant Drug Development, Regulation, and CommercializationAn Indian Industry Perspective
    Niharika Sahoo
    Padmavati Manchikanti
    BioDrugs, 2011, 25 : 105 - 113
  • [33] Science, politics, and the pharmaceutical industry: Controversy and bias in drug regulation
    Green, W
    POLITICS AND THE LIFE SCIENCES, 1997, 16 (02) : 333 - 334
  • [34] Regulation in an episodic policy making environment: The water industry in England and Wales
    Maloney, WA
    PUBLIC ADMINISTRATION, 2001, 79 (03) : 625 - 642
  • [35] Conflicting Interests: Development Politics and the Environmental Regulation of the Alberta Oil Sands Industry, 1970-1980
    Longley, Hereward
    ENVIRONMENT AND HISTORY, 2021, 27 (01) : 97 - 125
  • [36] PROFESSIONAL VERSUS CONSUMER INTERESTS IN REGULATION - THE CASE OF THE UNITED-STATES CHILD-CARE INDUSTRY
    LOWENBERG, AD
    TINNIN, TD
    APPLIED ECONOMICS, 1992, 24 (06) : 571 - 580
  • [37] Clarifying industry’s concerns over regulation of drug device combinations
    Milmo, Sean
    Pharmaceutical Technology, 2019, 43 (07) : 10 - 12
  • [38] Cloud-based data systems in drug regulation: an industry perspective
    Robertson, Andrew S.
    Malone, Hilary
    Bisordi, Fabio
    Fitton, Helen
    Garner, Carlos
    Holdsworth, Stacy
    Honig, Peter
    Hukkelhoven, Mathias
    Kowalski, Robert
    Milligan, Sandra
    O'Dowd, Liza
    Roberts, Khyati
    Rohrer, Michelle
    Stewart, Jerry
    Taisey, Mark
    Thakkar, Roopal
    Van Baelen, Karin
    Wegner, Max
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (06) : 365 - 366
  • [39] Science, politics, and the pharmaceutical industry: Controversy and bias in drug regulation.
    Lindee, S
    TECHNOLOGY AND CULTURE, 1998, 39 (02) : 336 - 338
  • [40] Advancing structured decision-making in drug regulation at the FDA and EMA
    Angelis, Aris
    Phillips, Lawrence D.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (02) : 395 - 405
12345